百济神州：第三季度总收入达14亿美元 同比增长41%

Core Insights - BeiGene (6160.HK) reported total revenue of $1.4 billion for Q3 2025, representing a year-over-year increase of 41% [1] - The global revenue for Brukinsa (Zebutinib) in the same quarter reached $1 billion, marking a 51% year-over-year growth [1] - The diluted earnings per American Depositary Share (ADS) under GAAP were $1.09, while the non-GAAP diluted earnings per ADS were $2.65 [1]